A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma

A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma

An antibody-drug conjugate (ADC) is a promising therapeutic modality because selective and effective delivery of an anti-cancer drug is achieved by drug-conjugated antibody-targeting cancer antigen. Glypican 1 (GPC1) is highly expressed in malignant tumors, including pancreatic ductal adenocarcinoma...

Full description

Bibliographic Details
Main Authors: Eri Munekage, Satoshi Serada, Shigehiro Tsujii, Keiichiro Yokota, Keita Kiuchi, Kenji Tominaga, Minoru Fujimoto, Mizuki Kanda, Sunao Uemura, Tsutomu Namikawa, Taisei Nomura, Ichiro Murakami, Kazuhiro Hanazaki, Tetsuji Naka
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Antibody-drug conjugate
Glypican-1
Pancreatic cancer
Esophageal squamous cell carcinoma
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558621000610

Internet

http://www.sciencedirect.com/science/article/pii/S1476558621000610

Similar Items